Clinical Trial Update: Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on BG2109 evaluating efficacy and safety during controlled ovarian hyperstimulation in ART procedures.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Assisted Reproductive Technology
• Controlled Ovarian Hyperstimulation

Drugs mentioned

• BG2109

Snippet

Sponsor: Bio Genuine (Shanghai) Biotech Co., Ltd. | Conditions: Assisted Reproductive Technology, Controlled Ovarian Hyperstimulation | Phase 2 | Status: UNKNOWN